BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND IDH2, P48735, 3418, ENSG00000182054, IDHM, mNADP-IDH, IDH, IDP, ICD-M AND Prognosis
181 results:

  • 1. [Research Progress of Isocitrate Dehydrogenase Mutation-Positive Acute Myeloid leukemia --Review].
    Ye F; Ma J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):630-633. PubMed ID: 38660877
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A Case of Chronic Eosinophilic leukemia with CSF3R-Mutant Clone and Transformed to Secondary Acute Myeloid leukemia.
    Wu Y; Yang X
    Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623671
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.
    Fruchtman H; Avigan ZM; Waksal JA; Brennan N; Mascarenhas JO
    Leukemia; 2024 May; 38(5):927-935. PubMed ID: 38600315
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis.
    Chang L; Lang M; Lin H; Cai H; Duan MH; Zhou DB; Cao XX
    Leukemia; 2024 Apr; 38(4):803-809. PubMed ID: 38388646
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
    Shimony S; Bewersdorf JP; Shallis RM; Liu Y; Schaefer EJ; Zeidan AM; Goldberg AD; Stein EM; Marcucci G; Lindsley RC; Chen EC; Ramos Perez J; Stein A; DeAngelo DJ; Neuberg DS; Stone RM; Ball B; Stahl M
    Leukemia; 2024 Apr; 38(4):762-768. PubMed ID: 38378841
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A comparative safety review of targeted therapies for acute myeloid leukemia.
    Dalgetty M; Leurinda C; Cortes J
    Expert Opin Drug Saf; 2023; 22(12):1225-1236. PubMed ID: 38014918
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Zhao S; Li Y; Xu J; Shen L
    Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. MLPA in the initial genetic screening of patients with acute myeloid leukemia.
    Yahya D; Hachmeriyan M; Ruseva T; Chervenkov T; Micheva I
    Rom J Intern Med; 2024 Mar; 62(1):44-51. PubMed ID: 37948316
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Identification and validation of a prognostic risk-scoring model based on the level of TIM-3 expression in acute myeloid leukemia.
    Huang W; Zheng S; Wang Q; Zhao N; Long Z
    Sci Rep; 2023 Sep; 13(1):15658. PubMed ID: 37730831
    [TBL] [Abstract] [Full Text] [Related]  

  • 10.
    Babakhanlou R; DiNardo C; Borthakur G
    Leuk Lymphoma; 2023; 64(11):1733-1741. PubMed ID: 37462435
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
    Tefferi A; Alkhateeb H; Gangat N
    Blood Cancer J; 2023 Jul; 13(1):108. PubMed ID: 37460550
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2023 Sep; 98(9):1465-1487. PubMed ID: 37357958
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. [Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid leukemia].
    Cao L; Jiang ZQ; Liu WJ; Sun Q; Zhu Y; Li JY; Qian SX; Hong M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):633-642. PubMed ID: 37356919
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of
    Liu H; Shi Y; Tao S; Li Y; Wang C; Yu L
    Hematology; 2023 Dec; 28(1):2223866. PubMed ID: 37313982
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Prognostic value of idh2R140 and idh2R172 mutations in patients with acute myeloid leukemia: a systematic review and meta-analysis.
    Qin Y; Shen K; Liu T; Ma H
    BMC Cancer; 2023 Jun; 23(1):527. PubMed ID: 37291515
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. New insights into the clinical characteristics of SETD2-mutated acute myeloid leukaemia.
    Zhang X; Wang Z; Sun J; Liu L; Qin J; Huang A; Yang M; Lou Y; Tang G; Mao L; Qian J; Wei J; Mai W; Meng H; Yang J; Tong H; Wang J; Yu W; Ni X; Jin J
    Br J Haematol; 2023 Jul; 202(1):111-115. PubMed ID: 37038274
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Clinical characteristics and prognostic significance of DNA methylation regulatory gene mutations in acute myeloid leukemia.
    Xu X; Wang H; Han H; Yao Y; Li X; Qi J; Cai C; Zhou M; Tang Y; Pan T; Zhang Z; Yang J; Wu D; Han Y
    Clin Epigenetics; 2023 Mar; 15(1):54. PubMed ID: 36991512
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. [Analysis of epigenetic modification gene mutations among patients with acute myeloid leukemia].
    Wei J; Qiu H; Zhou H; Chen Z; Miao L; Wang Y; Zhao L; Cai Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2023 Apr; 40(4):435-441. PubMed ID: 36972938
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Recent advances in targeted therapies in acute myeloid leukemia.
    Bhansali RS; Pratz KW; Lai C
    J Hematol Oncol; 2023 Mar; 16(1):29. PubMed ID: 36966300
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors.
    Aldea M; Tagliamento M; Bayle A; Vasseur D; Vergé V; Marinello A; Danlos FX; Blanc-Durand F; Bernard E; Cerbone L; Mosele MF; Renneville A; Hadoux J; Loriot Y; Sakkal M; Vozy A; Sarkozy C; Smolenschi C; Nicotra C; Martin-Romano P; Boccon-Gibod C; Habza W; Lazarovici J; Ponce S; Hollebecque A; Marzac C; Lacroix L; Barlesi F; André F; Besse B; Rouleau E; Italiano A; Micol JB
    JCO Precis Oncol; 2023 Mar; 7():e2200583. PubMed ID: 36862966
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 10.